Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nirogacestat versus placebo in progressing desmoid tumors
NL-OMON55814Phase 3Completed
- Sponsor
- SpringWorks Therapeutics
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nirogacestat in aggressive fibromatosis (AF) (3 arms), sponsored by SpringWorks Therapeutics. Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
nirogacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on NL-OMON55814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55814.